Cargando…
Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
PURPOSE: TAK-639 is a topical, nine-amino acid, synthetic, C-type natriuretic peptide analog in Phase 1 development for the treatment of ocular hypertension (OHT) and primary open-angle glaucoma (POAG). TAK-639 is postulated to lower intraocular pressure (IOP) through a novel mechanism of action (MO...
Autores principales: | Martin, Patrick, Cohen, Alisa, Uddin, Sharif, Epelbaum, Laura, Josiah, Serene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093107/ https://www.ncbi.nlm.nih.gov/pubmed/32256046 http://dx.doi.org/10.2147/OPTH.S242932 |
Ejemplares similares
-
639 Impact of De-escalating Contact Precautions on MRSA Infection Rates in an Academic Medical Center
por: Edmond, Michael, et al.
Publicado: (2014) -
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018) -
Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Iester, Michele
Publicado: (2008) -
Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018) -
Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
por: Singh, Inder P., et al.
Publicado: (2020)